Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cymabay Therapeutics (NQ: CBAY )

20.88 -0.89 (-4.09%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cymabay Therapeutics

< Previous 1 2 3 4 Next >
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
CymaBay Therapeutics: Q1 Earnings Insights
CymaBay Therapeutics (NASDAQ:CBAY) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Vallon Pharmaceuticals (NASDAQ:VLON) shares moved upwards by 94.7% to $2.2 during Friday's pre-market session. The company's market cap stands at $14.9 million. 
Via Benzinga
The Daily Biotech Pulse: Moderna Files For 2nd COVID Booster Shot Authorization, Lexicon Secures Debt Funding, Amneal Gets Sub-License to Manufacture Generic COVID Pill
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
CymaBay Therapeutics: Q4 Earnings Insights
CymaBay Therapeutics (NASDAQ:CBAY) reported its Q4 earnings results on Thursday, March 17, 2022 at 04:00 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
The Daily Biotech Pulse: AbbVie's Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
Earnings Scheduled For March 17, 2022
Companies Reporting Before The Bell • TransGlobe Energy (NASDAQ:TGA) is estimated to report earnings for its fourth quarter. • Ikena Oncology (NASDAQ:IKNA) is... 
Via Benzinga
A Preview Of CymaBay Therapeutics's Earnings
CymaBay Therapeutics (NASDAQ:CBAY) is set to give its latest quarterly earnings report on Thursday, 2022-03-17. Here's what investors need to know before the announcement.... 
Via Benzinga
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
Via Benzinga
Mid-Afternoon Market Update: Crude Oil Drops 2%; Limelight Networks Shares Spike Higher
Toward the end of trading Friday, the Dow traded down 0.59% to 34,509.34 while the NASDAQ fell 1.38% to 13,958.13. The S&P also fell, dropping, 0.99% to 4,438.28. The U.S. has... 
Via Benzinga
Mid-Day Market Update: Dow Falls 100 Points; Netflix Shares Plummet
Midway through trading Friday, the Dow traded down 0.33% to 34,602.05 while the NASDAQ fell 1.27% to 13,974.28. The S&P also fell, dropping, 0.75% to 4,449.20. The U... 
Via Benzinga
34 Stocks Moving In Friday's Mid-Day Session
Gainers Blue Star Foods Corp. (NASDAQ: BSFC) shares jumped 180% to $5.32 after gaining around 9% on Thursday. Bon Natural Life Limited (NASDAQ: BON) shares gained 22% to $3.91.... 
Via Benzinga
Mid-Morning Market Update: Markets Down; Schlumberger Earnings Top Views
Following the market opening Friday, the Dow traded down 0.24% to 34,632.21 while the NASDAQ fell 1.37% to 13,959.79. The S&P also fell, dropping, 0.88% to 4,443.39. The U.S.... 
Via Benzinga
4 Penny Stocks Insiders Are Buying: CymaBay Therapeutics, Avalo Therapeutics And More
US stock futures traded lower this morning after Netflix, Inc. (NASDAQ: 
Via Benzinga
The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill Supply Deal With US, Roche's Spark Therapeutics Reports Positive Gene Therapy Readout, EDAP Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Roche's Spark Subsidiary Reports Positive Phase 1/2 Data For Hemophilia... 
Via Benzinga
CymaBay Therapeutics Inc. (CBAY) Q3 2021 Earnings Call Transcript
CBAY earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Voyager Therapeutics (NASDAQ:VYGR) shares moved upwards by 44.73% to $3.58 during Wednesday's regular session. Voyager Therapeutics's stock is trading at a... 
Via Benzinga
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at... 
Via Benzinga
Exposures Product Safety
CymaBay Therapeutics Inc. (CBAY) Q2 2021 Earnings Call Transcript
CBAY earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
CymaBay Secures $100M Non-Dilutive Funding To Fund Seladelpar Development Program
CymaBay Therapeutics Inc (NASDAQ: CBAY) has received $100 million in non-dilutive financing from Abingworth to fund the Phase 3 development program for... 
Via Benzinga
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,... 
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2021
Upgrades Piper Sandler upgraded the previous rating for Boston Properties Inc (NYSE:BXP) from Neutral to Overweight. Boston Properties earned $1.56 in the first quarter,... 
Via Benzinga
CymaBay Therapeutics Inc. (CBAY) Q1 2021 Earnings Call Transcript
CBAY earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.